Skip to content

Collegium Pharmaceutical, Inc. COLL Symproic and other — 2027

Similar metrics at other companies

Ducommun logo
DCOStructural Systems — 2027
$7.44M0.0%
Ducommun logo
DCOElectronic Systems — 2027
$9.29M0.0%
Ducommun logo
DCOStructural Systems — 2026
$7.44M-0.3%
Ducommun logo
DCOElectronic Systems — 2026
$9.29M0.0%
Nasdaq, Inc. logo
NDAQOther — 2027
$7M0.0%
Ducommun logo
DCOElectronic Systems — 2029
$5.28M-43.2%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.

The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s symproic and other — 2027?
Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — 2027 of $7.29M in Q4 2025.
What does symproic and other — 2027 mean?
Represents the projected or actual financial performance metric for the Symproic segment specifically for the fiscal year 2027. It is used by investors to model the sustainability and growth trajectory of the product line beyond the immediate term.